Meeting
2011 ASCO Annual Meeting
A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.
Authors
M. Ryu
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
M. Ryu , S. H. Park , B. Ryoo , S. Im , H. Kwon , S. S. Lee , S. R. Park , B. W. Kang , Y. Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT01091207
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10010)
Abstract #
10010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
First Author: Axel Le Cesne
Poster
2014 ASCO Annual Meeting
Interrelationship of primary and secondary mutations in gastrointestinal stromal tumors during TKI therapy.
First Author: Peter Hohenberger
Poster
2011 Gastrointestinal Cancers Symposium
Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial.
First Author: Jean-Yves Blay
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
First Author: Suzanne George